U.S. Markets closed
S&P 500
3,351.28+2.12(+0.06%)Nasdaq
11,010.98-97.09(-0.87%)Russell 2000
1,569.18+24.56(+1.59%)
AVEO Pharmaceuticals, Inc. (AVEO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6000+0.0400 (+0.88%)
At close: 4:00PM EDT
4.5900 -0.01 (-0.22%)
After hours: 5:31PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 4.5600 |
| Open | 4.5600 |
| Bid | 4.5500 x 1000 |
| Ask | 4.5900 x 1400 |
| Day's Range | 4.4400 - 4.6150 |
| 52 Week Range | 2.2300 - 11.2000 |
| Volume | 189,408 |
| Avg. Volume | 765,281 |
| Market Cap | 118.706M |
| Beta (5Y Monthly) | 1.52 |
| PE Ratio (TTM) | 164.29 |
| EPS (TTM) | 0.0280 |
| Earnings Date | Apr 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.67 |
- Zacks
Earnings Preview: AVEO Pharmaceuticals (AVEO) Q2 Earnings Expected to Decline
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin
AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin.
- Zacks
New Strong Sell Stocks for July 1st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
© 2020 Verizon Media. All rights reserved.
